
    
      This is a four-part Phase 2b study comprised of a 16-week, double-blind, placebo-controlled,
      Induction Period, a 12-week double-blind, placebo-controlled, Maintenance Period, a 24-week,
      Open-label Period and a post-treatment 28 week observational safety follow-up period designed
      to evaluate the short-term efficacy and the short- and long term safety of brazikumab in
      participants with moderate to severe, active Crohn's disease (CD) who have failed or are
      intolerant to anti-TNFÎ± therapy as determined by the Investigator.
    
  